XTAI
3030
Market cap2.32bUSD
Oct 08, Last price
313.50TWD
1D
0.00%
1Q
4.85%
Jan 2017
720.68%
IPO
800.86%
Name
Test Research Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Test Research, Inc. (TRI) is a global enterprise that designs, engineers, manufactures, services, and distributes automated inspection and testing machinery. Its operations span across Asia, the Americas, Europe, and other international markets. The company's product line includes advanced optical inspection solutions, such as 3D solder paste inspection, automated optical inspection for both pre-reflow and post-reflow stages, and automated X-ray inspection systems. Additionally, TRI manufactures defect analyzers and in-circuit testers. Expanding its offerings, Test Research, Inc. also delivers intelligent factory and AI-driven solutions, along with comprehensive yield management systems. These sophisticated testing and inspection technologies are tailored for key sectors, including the automotive, semiconductor, and telecommunications industries. TRI is committed to extensive after-sales support, which comprises services like troubleshooting, in-depth failure analysis, routine calibration, complete system maintenance, and warranty provisions for parts and accessories. Established in 1989, the company's corporate headquarters are situated in Taipei City, Taiwan.
Key people
Kaun-Yuan Chen
Finance Manager · since 2019
Chieh-Yuan Chen
Chairman of the Board, General Manager · since 1990
Ming-Chuan Cai
Director · since 2017
Chin-Lung Chen
Director · since 2017
Director · since 2002
Chiang-Huai Lin
Deputy General Manager-Global Sales Division, Director · since 2000
Mei-Jin Chen
Independent Director · since 2017
Liang-Chia Chen
Independent Director · since 2017
Independent Director · since 2017
Chi-Jui Huang
Independent Director · since 2023
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||